SLC7A8 Gene - GeneCards | LAT2 Protein | LAT2 Antibody
2024年12月25日 · SLC7A8 (Solute Carrier Family 7 Member 8) is a Protein Coding gene. Diseases associated with SLC7A8 include Lysinuric Protein Intolerance and Hartnup Disorder. …
SLC7A8 is a key amino acids supplier for the metabolic ... - PubMed
2022年11月16日 · Here, we found that ILC2s selectively express Slc7a8, encoding a transporter for arginine and large amino acids. Slc7a8 was expressed in ILC2s in a tissue-specific manner …
谷氨酰胺代谢途径在肿瘤化疗耐药中的功能机制 - PMC
激活的mtorc1可通过抑制蛋白酶体活性增强slc7a8稳定性，从而促使肿瘤细胞从细胞外环境摄取更多的谷氨酰胺，并合成谷胱甘肽，从而进一步诱导其对吉西他滨耐药 。
SLC7A8 is a key amino acids supplier for the metabolic programs …
Here, we show that SLC7A8 is the key amino acid transporter in ILC2s. Slc7a8 deletion in lymphocytes reduced ILC2s and attenuated responses to helminth infection and house dust …
SLC7A8 solute carrier family 7 member 8 [ (human)]
2025年2月8日 · SLC7A8 overexpression inhibits the growth and metastasis of lung adenocarcinoma and is correlated with a dismal prognosis. Identification and verification of …
溶质载体家族 7 成员 8（SLC7A8）基因 | MCE
Broad expression in kidney (RPKM 77.2), prostate (RPKM 18.0) and 18 other tissues. 启用多种功能，包括中性氨基酸跨膜转运蛋白活性；甲状腺激素跨膜转运体活性；和毒素跨膜转运蛋白活 …
SLC7A8 solute carrier family 7 member 8 [ Homo sapiens …
2024年12月10日 · Title: The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer. These preliminary data suggest that a …
SLC7A8 overexpression inhibits the growth and metastasis of lung ...
2024年1月18日 · The downregulation of SLC7A8 was related to a dismal prognosis and immune cell infiltration in LUAD. Increasing the expression of <i>SLC7A8</i> inhibited the growth and …
Slc7a8 solute carrier family 7 (cationic amino acid transporter, y+ ...
2025年2月8日 · Acts upstream of or within L-amino acid transport. Located in apical plasma membrane. Is expressed in several structures, including alimentary system; central nervous …
The solute carrier SLC7A8 is a marker of favourable prognosis in …
SLC7A8 appears to play a role in BC and is a marker for favourable prognosis in the most predominant, ER+ low proliferative/luminal A, BC subtype. Functional assessment is …